This leads to the clinical phenomenon that patients who have a low expression level of YBX3 tend to be more sensitive to immune checkpoint blockade therapy, suggesting that YBX3 expression endows cancer cells with a more versatile regulatory response that enables them to evade immune checkpoint inhibitors. Here, YBX3 is linked to cancer.